Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.39 |
| ▸ | C1S | P09871 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 4/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5089771 | 0.87 | PIM1 (0.42) | CHEK1CDC7CCNT1CDK9HASPIN | |
| SCHEMBL5095241 | 0.84 | CDC7 (0.47) | CHEK1HSD11B1CDC7CCNT1CDK9 | |
| SCHEMBL5095235 | 0.84 | CDC7 (0.47) | CHEK1HSD11B1CDC7CCNT1CDK9 | |
| Trifluoroacetic Acid SCHEMBL5092686 | 0.84 | CHEK1 (0.40) | CHEK1HSD11B1CDC7CCNT1CDK9 | |
| Trifluoroacetic Acid SCHEMBL5092991 | 0.83 | PBK (0.44) | CHEK1HSD11B1CDC7CCNT1CDK9 | |
| SCHEMBL5095386 | 0.82 | CHEK1 (0.42) | CHEK1HSD11B1CDC7CCNT1CDK9 | |
| SCHEMBL5095393 | 0.82 | CHEK1 (0.42) | CHEK1HSD11B1CDC7CCNT1CDK9 | |
| Trifluoroacetic Acid SCHEMBL5089686 | 0.81 | CDC7 (0.36) | CHEK1HSD11B1CDC7CCNT1CDK9 | |
| Trifluoroacetic Acid SCHEMBL5095358 | 0.81 | CDC7 (0.36) | CHEK1HSD11B1CDC7CCNT1CDK9 | |
| SCHEMBL5095489 | 0.81 | CHEK1 (0.43) | CHEK1CDC7CCNT1CDK9HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371862-B2 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2008-05-13 | — | — | US | claimed |
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2007-05-17 | — | — | US | claimed |
| EP-1960399-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Pfizer Italia S.r.l. (IT) | 2008-08-27 | — | — | EP | disclosed |
| US-7371862-B2 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2008-05-13 | — | — | US | disclosed |
| WO-2007054508-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2007-05-18 | — | — | WO | disclosed |
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K6, MAP3K1 | CHEK1 251/4885HSD11B1 1385/4885C1S 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.